Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: The role of cephalosporins in antimicrobial therapy

International Journal of Antimicrobial Agents

Volumn 23, Issue 3, 2004, Pages 240-246

  Jones, Mark E ^a   Karlowsky, James A ^a   Draghi, Deborah C ^a   Thornsberry, Clyde ^b   Sahm, Daniel F ^a   Nathwani, Dilip ^c  

^a Focus Technologies Incorporated   (United States)

^b Tayside University Hospitals ^*

^c NHS TAYSIDE   (United Kingdom)

Author keywords

Antibiotic resistance; Bone infections; Osteomyelitis; Surveillance

Indexed keywords

BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATION; BONE INFECTION; CONTROLLED STUDY; DRUG ACTIVITY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS; UNITED STATES;

EID: 1442312068     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.08.007     Document Type: Article

References (20)

1. Lew D.P., Waldvogel F.A. Osteomyelitis. N Engl J Med. 36:1997;999-1007.
2. Tice A.D., Hoaglund P.A., Schoultz D.A. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am. J. Med. 114:2003;723-728.
3. Stengel D., Bauwens K., Sehouli J., Ekkernkamp A., Porzsolt F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis. 1:2001;175-188.
4. Prabhakar M.S., Bergquist M.S., Mader J.T. Osteomyelitis. Curr Treat Option Infect Dis. 2:2000;187-199.
5. Livermore D.M. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 8:1995;557-584.
6. Casewell M.W. New threats to the control of methicillin resistant Staphylococcus aureus. J Hosp Infect. 30:1995;465-471.
7. Sahm D.F., Marsilio M.K., Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the surveillance network database - USA. Clin Infect Dis. 29:1999;259-263.
8. Methods for dilution antimicrobial tests for bacteria that grow aerobically. NCCLS document M7-A5. 5th ed. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
9. Performance standards for antimicrobial susceptibility testing. NCCLS document M100-S11. Eleventh Informational Supplement. Wayne, PA: National Committee for Clinical Laboratory Standards; 2001.
10. Hadziyannis E., Tuohy M., Thomas L., Procop G.W., Washington J.A., Hal G.S. Screening and confirmatory testing for extended spectrum β-lactamases (ESBL) in Escherichia coli. Diagn Microbiol Infect Dis. 36:2000;113-117.
11. Carek P.J., Dickerson L.M., Sack J.L. Diagnosis and management of osteomyelitis. Am Fam Physician. 63:2001;2413-2420.
12. Cunha B.A. Osteomyelitis in elderly patients. Clin Infect Dis. 35:2002;287-293.
13. ®) Database - USA. Int J Antimicrob Agents. 19:2002;413-426.
14. Lovering A.M., Walsh T.R., Bannister G.C., MacGowan A.P. The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. J Antimicrob Chemother. 47:2001;483-486.
15. Scaglione F, De Martini G, Peretto L, Ghezzi R, Baratelli M, Arcidiacono et al. Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty. Antimicrob Agents Chemother 1997;41: 2292-94
16. Nathwani D. Place of parenteral cephalosporins in the ambulatory setting: clinical evidence. Drugs. 59:2000;37-49.
17. Tice A. The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: data from the outpatient parenteral antimicrobial therapy outcomes registries. Chemotherapy. 47:2001;5-16.
18. Nathwani D., Barlow G.D., Ajdukiewicz K., Gray K., Morrison J., Clift B.et al. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J Antimicrob Chemother. 51:2003;391-396.
19. Moise P.A., Forrest A., Birmingham M.C., Schentag J.J. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother. 50:2002;1017-1026.
20. Guglielmo B.J., Luber A.D., Paletta D. Jr., Jacobs R.A. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis. 30:2000;205-207.